Vericel to Report Fourth-Quarter and Full-Year 2025 Financial Results on February 26, 2026
Vericel (NASDAQ:VCEL) will report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vericel (NASDAQ:VCEL) will report fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026.
Management will host a conference call and webcast at 8:30 a.m. ET. Presentation slides will be available on the Investor Relations website and a replay will be available through February 26, 2027. Telephone participants may dial 800-330-6730 or +1-312-471-1351 with passcode 227995.
Details
News Market Reaction – VCEL
On Feb 12, the day this news came out, VCEL closed 1.91% below the previous close.
Data tracked by StockTitan Argus for the Feb 12 session.
Key Figures
- Earnings call date
- February 26, 2026
- Scheduled fourth-quarter and full-year 2025 results
- Earnings call time
- 8:30 a.m. ET
- Conference call and webcast start time
- Webcast replay end
- February 26, 2027
- Webcast replay availability period
- US dial-in number
- 800-330-6730
- Telephone participation in earnings call
- International dial-in
- +1-312-471-1351
- Non-U.S. access to earnings call
- Call passcode
- 227995
- Passcode required for telephone participants
Historical Context
-
Preliminary 2025 revenue, margin and cash updates ahead of full results.
-
Announcement of presentation at 44th Annual J.P. Morgan Healthcare Conference.
-
Fireside chat at Stephens Investment Conference with webcast access for investors.
-
Record Q3 revenue, strong MACI growth, profitability and reaffirmed 2025 guidance.
-
Scheduling of Q3 2025 earnings call and webcast with replay details.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its fourth-quarter and full-year 2025 financial results on Thursday, February 26, 2026. Vericel’s management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.
The live webcast can be accessed on the Investor Relations section of the Vericel website at http://investors.vcel.com/events-presentations. Presentation slides for the conference call will be available on the webcast and on the website. A replay of the webcast will be available until February 26, 2027.
To participate by telephone, dial 800-330-6730 or +1-312-471-1351 if connecting from outside the U.S. When connected, please use passcode: 227995.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.